Grade 3 or 4 AEs were neutropenia (n = 9), lymphopenia (n = 6), hypophosphatemia (n = 6), raised alanine aminotransferase (n = 6), results interpreted that Crizotinib is well tolerated with durable, rapid responses in patients with ALK-positive NSCLC. This evidence concerns the gene ALK and lymphopenia.